HNSCC
MCID: SQM013
MIFTS: 70

Squamous Cell Carcinoma, Head and Neck (HNSCC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

Aliases & Descriptions for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 54 13
Squamous Cell Carcinoma of the Head and Neck 38 12 50 25 66 14 69
Head and Neck Squamous Cell Carcinoma 12 50 25 56 14
Hnscc 50 25 56 66 52
Carcinoma, Squamous Cell of Head and Neck 50 42
Squamous Cell Carcinoma of Head and Neck 56 29
Head and Neck Cancer 50 41
Squamous Cell Carcinoma, Head and Neck, Somatic 54
Squamous Cell Carcinomas of Head and Neck 12
Carcinoma of the Head and Neck 12
Cancer of Head and Neck 69
Scchn 25

Characteristics:

Orphanet epidemiological data:

56
squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

HPO:

32
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 54 275355
Disease Ontology 12 DOID:5520
NCIt 47 C34447
Orphanet 56 ORPHA67037
MESH via Orphanet 43 C535575
UMLS via Orphanet 70 C1168401
MedGen 40 C1168401
UMLS 69 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

MedlinePlus : 41 head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. most begin in the moist tissues that line the mouth, nose, and throat. symptoms include a lump or sore that does not heal a sore throat that does not go away trouble swallowing a change or hoarseness in the voice head and neck cancers are twice as common in men. using tobacco or alcohol increases your risk. in fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. infection with hpv is a risk factor for some head and neck cancers. to diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. you will have a biopsy, where a sample of tissue is taken out and examined under a microscope. it is the only test that can tell for sure if you have cancer. if found early, these cancers are often curable. treatments may include surgery, radiation therapy, chemotherapy, or a combination. treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. nih: national cancer institute

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to oral cancer and thyroid cancer, and has symptoms including squamous cell carcinoma, coughing and halitosis. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Integrin Pathway and Cytokine Signaling in Immune system. The drugs Erbitux and Ethyol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and growth/size/body region

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference : 25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases : 50 cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). these squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. at least 75 % of head and neck cancers are caused by tobacco and alcohol use. infection with cancer-causing types of human papillomavirus (hpv), especially hpv-16, is a risk factor for some types of head and neck cancers. the symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments. last updated: 8/3/2015

UniProtKB/Swiss-Prot : 66 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Description from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 oral cancer 11.1
2 thyroid cancer 11.1
3 salivary gland cancer 10.8
4 salivary gland cancer, adult 10.8
5 villoglandular endometrial endometrioid adenocarcinoma 10.5 CCND1 PTEN TP53
6 childhood embryonal testis carcinoma 10.5 EGFR PTEN TP53
7 urethral villous adenoma 10.5 CD44 CDKN2A EGFR
8 glioma susceptibility 2 10.5 EGFR PIK3CA PTEN
9 decubitus ulcer 10.5 CCND1 CDKN2A STAT3
10 oro-mandibular-limb hypogenesis syndrome 10.5 CCND1 CDKN2A TP53
11 thymus adenocarcinoma 10.5 EGFR MMP2 MMP9
12 adult syndrome 10.5 PIK3CA PTEN TP53
13 urethral verrucous carcinoma 10.5 CDKN2A PTEN TP53
14 cervical verrucous carcinoma 10.4 CCND1 CDKN2A TP53
15 chronic monocytic leukemia 10.4 CDKN2A EGFR TP53
16 thymus squamous cell carcinoma 10.4 CDKN2A EGFR TP53
17 uterine disease 10.4 CDKN2A PIK3CA TP53
18 uterine cervix leukoplakia 10.4 CDKN2A FHIT TP53
19 sengers syndrome 10.4 CDH1 CDKN2A EGFR PTEN
20 tumor of exocrine pancreas 10.4 CDKN2A EGFR VEGFA
21 senile atrophy of choroid 10.4 MMP2 MMP9 VEGFA
22 nasopharyngeal carcinoma 10.4 CDKN2A EGFR PTEN TP53
23 secondary hyperparathyroidism of renal origin 10.4 CDKN2A EGFR TP53
24 cleft palate cardiac defect ectrodactyly 10.4 CCND1 EGFR TP53 VEGFA
25 stenosis of lacrimal punctum 10.4 CCND1 CTTN EGFR PIK3CA
26 coronary stenosis 10.4 PIK3CA TP53 VEGFA
27 cryoglobulinemia 10.4 CDKN2A FHIT STAT3 TP53
28 pyomyositis 10.4 CDH1 CDKN2A EGFR TP53
29 spastic paraplegia 1 10.4 EGFR PIK3CA TP53 VEGFA
30 advanced sleep phase syndrome 10.4 CCND1 CDH1 CDKN2A TP53
31 bronchiolitis obliterans with obstructive pulmonary disease 10.4 CCND1 CDH1 PIK3CA
32 retroperitoneal neuroblastoma 10.4 CD44 PIK3CA PTEN TP53
33 striated muscle rhabdoid tumor 10.4 CCND1 CDKN2A MMP2 MMP9
34 facio skeletal genital syndrome rippberger type 10.4 MMP2 MMP9
35 reactive arthritis 10.4 EGFR PIK3CA TP53
36 childhood-onset cerebral x-linked adrenoleukodystrophy 10.4 CDH1 CDKN2A EGFR TP53
37 paroxysmal nocturnal hemoglobinuria 10.4 CDH1 CDKN2A EGFR TP53
38 anaerobic meningitis 10.4 EGFR TNFRSF10B VEGFA
39 adult oligodendroglioma 10.4 CDKN2A EGFR PTEN TP53
40 linitis plastica 10.4 CDH1 TP53
41 placental site trophoblastic tumor 10.4 CDKN2A TP53 VEGFA
42 interstitial lung disease 10.4 CDKN2A EGFR PTEN TP53 VEGFA
43 immunodeficiency due to a late component of complement deficiency 10.4 EGFR TP53 VEGFA
44 spinal muscular atrophy with progressive myoclonic epilepsy 10.4 CCND1 CDKN2A FHIT TP53
45 his bundle tachycardia 10.4 CCND1 EGFR TP53
46 prostatic adenoma 10.4 CDKN2A EGFR PTEN TP53 VEGFA
47 oral squamous cell carcinoma 10.4 CDH1 EGFR TP53 VEGFA
48 statin toxicity 10.4 CCND1 FHIT MMP9 TP53
49 allergic contact dermatitis 10.4 CDKN2A EGFR TP53
50 adenoid squamous cell carcinoma 10.4 CDKN2A MMP2 MMP9

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Symptoms by clinical synopsis from OMIM:

275355

Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

32
id Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 32 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


coughing, halitosis, snoring, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 CD44 CDH1 CDKN2A ING1 MMP2 PIK3CA

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 CDH1 CDKN2A CTTN CXCL14 EGFR ING1
2 immune system MP:0005387 10.44 CCND1 CD44 CDH1 CDKN2A CTTN CXCL14
3 cardiovascular system MP:0005385 10.42 TP53 VEGFA CCND1 CD44 CDH1 CDKN2A
4 homeostasis/metabolism MP:0005376 10.42 CCND1 CD44 CDH1 CDKN2A CXCL14 EGFR
5 cellular MP:0005384 10.41 PTEN STAT3 TP53 VEGFA CCND1 CD44
6 hematopoietic system MP:0005397 10.4 CCND1 CD44 CDKN2A CTTN CXCL14 EGFR
7 mortality/aging MP:0010768 10.4 VEGFA CCND1 CD44 CDH1 CDKN2A CTTN
8 behavior/neurological MP:0005386 10.35 VEGFA CCND1 CD44 CDKN2A CXCL14 ING1
9 digestive/alimentary MP:0005381 10.33 CCND1 CD44 MMP9 PTEN STAT3 TP53
10 endocrine/exocrine gland MP:0005379 10.32 CDH1 CDKN2A EGFR ING1 PIK3CA PTEN
11 integument MP:0010771 10.3 CCND1 CD44 CDH1 CDKN2A EGFR FHIT
12 neoplasm MP:0002006 10.3 CD44 CDH1 CDKN2A EGFR FHIT ING1
13 embryo MP:0005380 10.24 CDH1 CDKN2A VEGFA CTTN EGFR PIK3CA
14 muscle MP:0005369 10.18 CD44 CDKN2A EGFR MMP2 MMP9 PIK3CA
15 nervous system MP:0003631 10.17 CCND1 CD44 CDKN2A EGFR MMP2 MMP9
16 liver/biliary system MP:0005370 10.11 CD44 CDKN2A CXCL14 EGFR PTEN STAT3
17 reproductive system MP:0005389 10.07 CCND1 CD44 CDH1 CDKN2A CTTN CXCL14
18 normal MP:0002873 10.02 CCND1 CD44 CDH1 EGFR MMP2 PTEN
19 no phenotypic analysis MP:0003012 10.01 CDH1 CDKN2A CTTN CXCL14 EGFR PIK3CA
20 renal/urinary system MP:0005367 9.92 CD44 CXCL14 EGFR MMP9 PTEN STAT3
21 respiratory system MP:0005388 9.9 CCND1 CD44 CDKN2A CTTN EGFR MMP2
22 skeleton MP:0005390 9.7 CCND1 CD44 CDKN2A EGFR MMP2 MMP9
23 vision/eye MP:0005391 9.36 CCND1 CD44 CDKN2A EGFR MMP2 MMP9

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb Approved February 2004
2
Ethyol 17 AMIFOSTINE Alza Approved December 8, 1995
3
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 493)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 205923-56-4 56842117 2333
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Ethanol Approved Phase 4,Phase 1 64-17-5 702
5
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
7
Petrolatum Approved Phase 4 8009-03-8
8 Titanium dioxide Approved Phase 4 13463-67-7
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124 9877265
12 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Cholinergic Agents Phase 4,Phase 3
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Mitomycins Phase 4,Phase 3,Phase 2
29 Anesthetics Phase 4,Phase 3,Phase 2
30 Central Nervous System Depressants Phase 4,Phase 2,Early Phase 1
31 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Anti-Allergic Agents Phase 4,Phase 2
33 mometasone furoate Phase 4 83919-23-7
34 Adjuvants, Anesthesia Phase 4
35 Analgesics, Opioid Phase 4,Phase 2
36 Anesthetics, General Phase 4
37 Anesthetics, Intravenous Phase 4
38 Narcotics Phase 4,Phase 2
39 arginine Nutraceutical Phase 4,Phase 2,Phase 1
40 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2,Phase 1
41 Tegafur Approved Phase 3,Phase 2 17902-23-7
42
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
43
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
44
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
45
Citalopram Approved Phase 3 59729-33-8 2771
46
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
47
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
48
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
49
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
50
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 1420)
id Name Status NCT ID Phase
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4
2 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4
3 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4
4 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4
5 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4
6 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
7 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
8 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Recruiting NCT02015650 Phase 4
9 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4
10 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4
11 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Active, not recruiting NCT00684385 Phase 4
12 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
13 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
14 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
15 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
16 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
17 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
18 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3
19 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3
20 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
21 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3
22 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3
23 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
24 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
25 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3
26 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Unknown status NCT01434394 Phase 2, Phase 3
27 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
28 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3
29 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3
30 Elective or Prophylactic Nodal Irradiation for Esophageal Cancer Unknown status NCT01551589 Phase 3
31 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3
32 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
33 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
34 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
35 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3
36 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
37 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3
38 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3
39 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3
40 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3
41 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
42 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3
43 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3
44 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3
45 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3
46 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
47 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3
48 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3
49 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3
50 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

39
Skin, Testes, Lymph Node, Salivary Gland, Breast, T Cells, Endothelial

Publications for Squamous Cell Carcinoma, Head and Neck

Variations for Squamous Cell Carcinoma, Head and Neck

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

66
id Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 307)
id Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh37 Chromosome 10, 89692878: 89692878
4 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh37 Chromosome 13, 111372083: 111372083
5 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh37 Chromosome 13, 111372086: 111372086
6 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh37 Chromosome 13, 111372014: 111372014
7 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
8 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
10 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
13 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
17 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
18 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
19 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
21 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
22 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
23 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
25 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
26 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
27 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
28 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
29 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
30 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
31 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
32 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
33 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
34 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
35 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
36 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
37 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
38 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
39 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
40 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
41 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
42 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
43 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
44 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
45 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
46 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
47 EGFR NM_005228.4(EGFR): c.2155G> C (p.Gly719Arg) single nucleotide variant Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
48 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
49 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
50 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh37 Chromosome 9, 21971017: 21971017

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 471)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM14452 PTCH1 skin,neck,carcinoma,NS c.2321G>A p.G774E 48
2 COSM29072 PTCH1 skin,neck,carcinoma,NS c.1067+1G>A p.? 48
3 COSM29053 PTCH1 skin,neck,carcinoma,NS c.833G>A p.W278* 48
4 COSM17483 PTCH1 skin,neck,carcinoma,NS c.1729-1G>T p.? 48
5 COSM17468 PTCH1 skin,neck,carcinoma,NS c.584G>T p.R195M 48
6 COSM516 KRAS skin,neck,carcinoma,NS c.34G>T p.G12C 48
7 COSM498 HRAS skin,neck,carcinoma,squamous cell carcinoma BRAF inhibitor related c.182A>T p.Q61L 48
8 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 38
9 COSM44310 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.738G>A p.M246I 38
10 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 38
11 COSM11196 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>T p.G245V 38
12 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 38
13 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 38
14 COSM43582 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.454C>T p.P152S 38
15 COSM44226 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.380C>T p.S127F 38
16 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 38
17 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 38
18 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 38
19 COSM10941 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.730G>A p.G244S 38
20 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 38
21 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 38
22 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 38
23 COSM44126 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.507G>A p.M169I 38
24 COSM10790 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.455C>T p.P152L 38
25 COSM43868 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.689C>T p.T230I 38
26 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 38
27 COSM44091 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>A p.R249K 38
28 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 38
29 COSM44577 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.921A>G p.A307A 38
30 COSM10834 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>A p.M237I 38
31 COSM45099 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.924G>A p.L308L 38
32 COSM10867 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>A p.G266E 38
33 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 38
34 COSM44428 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.741C>T p.N247N 38
35 COSM43621 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.809T>G p.F270C 38
36 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 38
37 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 38
38 COSM10726 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.856G>A p.E286K 38
39 COSM45046 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>C p.R181P 38
40 COSM44415 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>C p.M237I 38
41 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 38
42 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 38
43 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 38
44 COSM43743 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.914A>G p.K305R 38
45 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 38
46 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 38
47 COSM10810 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>T p.C242F 38
48 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 38
49 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 38
50 COSM45353 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673G>A p.V225I 38

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 CXCL14 EGFR MMP2 MMP9 PIK3CA PTEN
2
Show member pathways
13.43 CCND1 CD44 EGFR MMP2 MMP9 PIK3CA
3
Show member pathways
12.98 CCND1 MMP9 PIK3CA PTEN STAT3 TP53
4
Show member pathways
12.97 CCND1 EGFR PIK3CA PTEN STAT3 VEGFA
5
Show member pathways
12.96 CCND1 CDH1 CDKN2A EGFR FHIT MMP2
6
Show member pathways
12.88 CDH1 PIK3CA PTEN STAT3 TP53 VEGFA
7
Show member pathways
12.84 CCND1 PIK3CA STAT3 TNFRSF10B TP53
8
Show member pathways
12.84 CCND1 EGFR MMP2 MMP9 PIK3CA PTEN
9
Show member pathways
12.73 CTTN MMP2 MMP9 PIK3CA VEGFA
10 12.67 CCND1 EGFR PIK3CA PTEN TP53 VEGFA
11
Show member pathways
12.66 EGFR MMP2 PIK3CA STAT3 TP53
12
Show member pathways
12.56 CCND1 CDH1 EGFR MMP2 MMP9 PIK3CA
13 12.49 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
14
Show member pathways
12.48 CCND1 PIK3CA PTEN STAT3 TP53
15
Show member pathways
12.45 CD44 PIK3CA STAT3 VEGFA
16
Show member pathways
12.45 CCND1 CDKN2A PTEN TNFRSF10B TP53
17 12.43 CCND1 CD44 CDKN2A EGFR MMP9 PIK3CA
18 12.41 CCND1 CDH1 CDKN2A TP53
19
Show member pathways
12.41 CCND1 CDH1 EGFR PIK3CA PTEN STAT3
20
Show member pathways
12.39 CCND1 EGFR PIK3CA STAT3 TP53
21 12.38 CCND1 CDKN2A PIK3CA STAT3 TP53
22 12.35 CD44 PIK3CA STAT3 TP53
23
Show member pathways
12.32 CCND1 PTEN TNFRSF10B TP53
24
Show member pathways
12.25 CCND1 EGFR PTEN TP53
25 12.21 CCND1 CDH1 EGFR PTEN TP53 VEGFA
26
Show member pathways
12.2 EGFR PIK3CA PTEN STAT3
27 12.19 CCND1 CDH1 EGFR MMP2 MMP9 STAT3
28 12.18 CCND1 PIK3CA PTEN TP53
29
Show member pathways
12.18 CCND1 EGFR MMP2 PIK3CA PTEN STAT3
30 12.17 MMP2 MMP9 PIK3CA TP53 VEGFA
31
Show member pathways
12.17 CCND1 EGFR PIK3CA PTEN STAT3
32 12.15 CCND1 CDKN2A PTEN TP53
33 12.14 EGFR MMP2 PTEN TNFRSF10B TP53
34 12.13 EGFR PIK3CA STAT3 TP53
35
Show member pathways
12.12 CCND1 CDKN2A EGFR PIK3CA STAT3 TP53
36
Show member pathways
12.11 EGFR PIK3CA STAT3 TP53
37 12.09 CCND1 EGFR MMP9 TP53
38 12.06 CCND1 CDKN2A PIK3CA PTEN TP53
39 12.05 CD44 CDH1 MMP2 MMP9
40 12.03 CCND1 CDKN2A EGFR PTEN TP53
41 12.03 CCND1 MMP2 MMP9 STAT3 TP53 VEGFA
42 11.99 EGFR PIK3CA STAT3 VEGFA
43 11.98 CCND1 MMP2 PIK3CA STAT3 VEGFA
44 11.98 CD44 CDKN2A CXCL14 ING1 PTEN TP53
45 11.94 CCND1 EGFR PTEN STAT3
46 11.89 CCND1 FHIT PIK3CA PTEN TP53
47 11.87 CCND1 CDH1 MMP2 MMP9
48 11.81 CDH1 CTTN PIK3CA
49 11.81 MMP9 PIK3CA STAT3
50 11.79 CDKN2A PIK3CA TP53

GO Terms for Squamous Cell Carcinoma, Head and Neck

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.89 CDKN2A ING1 PTEN STAT3 TP53
2 cell proliferation GO:0008283 9.88 EGFR PTEN RPS27 STAT3 TP53
3 angiogenesis GO:0001525 9.87 MMP2 PIK3CA PTEN VEGFA
4 positive regulation of apoptotic process GO:0043065 9.83 CDKN2A ING3 MMP9 PTEN TP53
5 leukocyte migration GO:0050900 9.81 CD44 MMP9 PIK3CA TNFRSF10B
6 liver development GO:0001889 9.77 CCND1 EGFR PIK3CA
7 positive regulation of protein phosphorylation GO:0001934 9.76 CCND1 EGFR MMP9 VEGFA
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 CD44 PIK3CA VEGFA
9 response to organic cyclic compound GO:0014070 9.71 CCND1 EGFR PTEN STAT3
10 phosphatidylinositol-mediated signaling GO:0048015 9.62 EGFR PIK3CA PTEN TP53
11 replicative senescence GO:0090399 9.58 CDKN2A TP53
12 regulation of mitochondrial membrane permeability GO:0046902 9.58 STAT3 TP53
13 response to estradiol GO:0032355 9.56 CCND1 EGFR PTEN STAT3
14 response to leptin GO:0044321 9.55 CCND1 STAT3
15 cellular response to leptin stimulus GO:0044320 9.54 PTEN STAT3
16 mitotic G1 DNA damage checkpoint GO:0031571 9.52 CCND1 TP53
17 response to organic substance GO:0010033 9.46 CCND1 CDH1 PTEN STAT3
18 response to UV-A GO:0070141 9.37 CCND1 EGFR
19 extracellular matrix disassembly GO:0022617 9.26 CD44 CDH1 MMP2 MMP9
20 negative regulation of apoptotic process GO:0043066 9.17 CD44 EGFR MMP9 PTEN STAT3 TP53
21 positive regulation of cell proliferation GO:0008284 10 CCND1 EGFR PTEN STAT3 VEGFA

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 EGFR FHIT MMP9 PTEN STAT3 TP53
2 protein binding GO:0005515 9.6 CCND1 CD44 CDH1 CDKN2A CTTN CXCL14
3 protein phosphatase binding GO:0019903 9.43 EGFR STAT3 TP53
4 protein kinase binding GO:0019901 9.43 CCND1 CDKN2A EGFR PTEN STAT3 TP53

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....